Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
Kadcyla Continues to Improve Survival in HER2-Positive Early-Stage Breast Cancer
moderators
Posts: 9,647
Kadcyla Continues to Improve Survival in HER2-Positive Early-Stage Breast Cancer
Dec 17, 2023
More than eight years of follow-up from the KATHERINE trial showed the continued survival benefits of Kadcyla over Herceptin for HER2-positive breast cancer with a high risk of recurrence. Read more…
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.